Conclusion: YDJDG reveals the potential to hasten the recovery period in COVID-19 patients with mild/moderate disease type or CD4 < 660 cells/μL by shortening the mean duration of fever and pulmonary exudative lesions. The gene discussed is CD4; the disease is COVID-19.